Phoenix Contact : Managed switches

Phoenix Contact now offers Series 7000 advanced managed switches.

Series 7000 advanced managed switches
Series 7000 advanced managed switches

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

The switches support the Device Level Ring (DLR) redundancy mechanism. With recovery times of less than three milliseconds, a switch-over can be performed quickly in the event that a failure occurs. This function increases the availability of the network. Up to six non-DLR-capable devices can be integrated into the ring with the 7000 switch.

The Series 7000 switches are particularly suitable for use in EtherNet/IP networks because they support the Common Industrial Protocol (CIP). Because of this feature, the switches can be directly integrated into the EtherNet/IP control system for seamless configuration and diagnostics.

Proven functions, such as IGMP snooping, multicast source detection, and auto-query port for intelligent multicast filtering, are also available on the switches to enhance network stability and usage in an EtherNet/IP system.

Coding, Marking, and Labeling Innovations Report
Explore our editor-curated report featuring cutting-edge coding, labeling, and RFID innovations from PACK EXPO 2024. Discover high-speed digital printing, sustainable label materials, automated labeling systems, and advanced traceability solutions that are transforming packaging operations across industries.
Access Report
Coding, Marking, and Labeling Innovations Report
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report